乳腺癌肝转移瘤CT长轴衰减分布:预测总生存的定量生物标志物
本研究基于前瞻性多中心III期贝伐珠单抗治疗转移性乳腺癌试验数据,纳入164例有≥15mm肝转移灶患者,比较长轴衰减分布(ADLA)测量与RECIST 1.1及Choi标准预测总生存的能力。ADLA以肿瘤长轴径线上各像素CT衰减值的标准差定义,25%下降为最佳缓解阈值;ADLA在最佳总体缓解和首次随访时点均优于RECIST和Choi标准。
要点
- ADLA测量为肿瘤长轴径线上各像素CT衰减值的标准差,25%下降定义为ADLA缓解。
- 最佳总体缓解时RECIST、Choi和ADLA均能识别总生存更优患者,首次随访时仅Choi和ADLA成功。
- ADLA在最佳总体缓解和首次随访时点的预测准确性均优于RECIST和Choi标准。
核心结论
- ADLA测量可能是癌症治疗反应的有用无创指标,且可能较容易利用现有放射科工作流程提取,值得进一步研究ADLA技术。
研究设计与样本
- 前瞻性、多中心、III期贝伐珠单抗治疗转移性乳腺癌试验的影像数据分析,纳入164例基线至少一个肝转移灶≥15mm的患者,评估最多两个靶肝病灶,采用RECIST 1.1、Choi标准和ADLA测量,参考标准为总生存。
诊断标准与关键数值
- ADLA定义为肿瘤长轴径线上各像素CT衰减值的标准差,最佳ADLA缓解阈值经Cox模型交叉验证确定为较基线下降25%。
临床应用与阅片要点
- 原文作者认为ADLA测量可能是癌症治疗反应的有用无创指标,并指出该测量可能较容易利用现有放射科工作流程提取,值得进一步研究。
局限性
- 原文结论指出值得进一步研究ADLA技术,提示当前证据尚需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The objective of our study was to compare attenuation distribution across the long-axis (ADLA) measurements, Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, and Choi criteria for predicting overall survival (OS) in patients with metastatic breast cancer treated with bevacizumab.
MATERIALS AND METHODS: We obtained HIPAA-compliant data from a prospective, multisite, phase 3 trial of bevacizumab for the treatment of metastatic breast cancer. For patients with one or more liver metastases measuring 15 mm or larger at baseline, we evaluated up to two target liver lesions using RECIST, Choi criteria, and ADLA measurements, with the latter defined as the SD of the CT attenuation values of each pixel along the tumor long-axis diameter. The optimal percentage change threshold for defining an ADLA response was computed by cross-validation analysis in a Cox model. The log-rank test was applied to evaluate RECIST, Choi criteria, and ADLA for discriminating patients with superior OS. The predictive accuracies of all three techniques were compared using Brier scores and areas under the ROC curve (AUC). All analyses were performed separately using best overall response (BOR) and response at the first follow-up time point (FU1).
RESULTS: One hundred sixty-four patients met the inclusion criteria. A 25% decrease in the ADLA measurement from baseline was the optimal ADLA response threshold for BOR and FU1. RECIST, Choi criteria, and ADLA successfully identified patients with superior OS when using BOR (RECIST, p = 0.02; Choi and ADLA, p < 0.001), but only Choi criteria and ADLA measurements were successful when using FU1 (RECIST, p = 0.43; Choi and ADLA, p < 0.001). In a direct comparison, ADLA measurements outperformed both RECIST and Choi criteria using BOR (95% CI for Brier score differences, ADLA-RECIST [-0.58 to -0.08] and ADLA-Choi [-0.55 to -0.06]; 95% CI for AUC differences, ADLA-RECIST [0.16-0.33] and ADLA-Choi [0.17-0.36]) as well as using FU1 (95% CI for Brier score differences, ADLA-RECIST [-0.77 to -0.08] and ADLA-Choi [-0.58 to -0.03]; 95% CI for AUC differences, ADLA-RECIST [0.22-0.39] and ADLA-Choi [0.01-0.22]).
CONCLUSION: ADLA measurements may be a useful noninvasive indicator of cancer treatment response. Because ADLA measurements may be extracted relatively easily using existing radiologist workflows, further investigation of the ADLA technique is warranted.
引用
- Abramson RG, Lakomkin N, Hainline A, et al. The Attenuation Distribution Across the Long Axis of Breast Cancer Liver Metastases at CT: A Quantitative Biomarker for Predicting Overall Survival. AJR Am J Roentgenol. 2017. PMID: 29064750. doi:10.2214/AJR.17.18249
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。